Drug price disruptor EQRx has signed a memorandum of understanding (MoU) with the UK’s National Health Service, outlining plans for a long-term partnership to supply medicines.
The firm’s lead oncology programs, aumolertinib and sugemalimab, have been granted Innovation Passport designations by the UK regulatory authorities.
This new pathway provides a route to faster approval, rolling review and continuous benefit-risk assessment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze